Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: Possible involvement in radioresistance

Cell Death and Disease

Volumn 5, Issue 11, 2014, Pages

  Dahan, P ^a   Martinez Gala, J ^a   Delmas, C ^a,b   Monferran, S ^a,c   Malric, L ^a   Zentkowski, D ^c   Lubrano, V ^c,d   Toulas, C ^a,b   Cohen Jonathan Moyal, E ^a,b   Lemarie, A ^a,c  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Institut Universitaire du Cancer de Toulouse   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITÉ TOULOUSE JEAN JAURÈS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; NESTIN; NOTCH1 RECEPTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; SONIC HEDGEHOG PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; BIRC5 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CARCINOGENICITY; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; IRRADIATION; MOUSE; NEURAL STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BRAIN TUMOR; CANCER STEM CELL; CELL SURVIVAL; METABOLISM; NUDE MOUSE; PATHOLOGY; PHENOTYPE; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE, NUDE; NEOPLASTIC STEM CELLS; PHENOTYPE; RADIATION TOLERANCE; RADIATION, IONIZING;

EID: 84927915783     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.509     Document Type: Article

References (74)

1. Park DM, Sathornsumetee S, Rich JN. Medical oncology: treatment and management of malignant gliomas. Nat Rev Clin Oncol 2010; 7: 75-77.
2. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22: 457-472.
3. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010; 80: 654-665.
4. Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol 2010; 20: 211-221.
5. Altaner C. Glioblastoma and stem cells. Neoplasma 2008; 55: 369-374.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
7. Charles N, Holland EC. Brain tumor treatment increases the number of cancer stemlike cells. Expert Rev Neurother 2009; 9: 1447-1449.
8. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Mol Oncol 2011; 5: 374-386.
9. Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010; 30: 10096-10111.
10. Lim YC, Roberts TL, Day BW, Harding A, Kozlov S, Kijas AW et al. A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells. Mol Cancer Ther 2012; 11: 1863-1872.
11. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
12. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11: 743-752.
13. Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. Int J Radiat Oncol Biol Phys 2012; 83: e43-e52.
14. Osuka S, Sampetrean O, Shimizu T, Saga I, Onishi N, Sugihara E et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 2012; 31: 627-640.
15. Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS, An S et al. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene 2012; 31: 4655-4666.
16. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010; 28: 17-28.
17. Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 2012; 72: 4119-4129.
18. Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011; 71: 7155-7167.
19. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007; 25: 2524-2533.
20. Yang YP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 2012; 227: 976-993.
21. Kim Y, Kim KH, Lee J, Lee YA, Kim M, Lee SJ et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2012; 92: 466-473.
22. Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 2012; 14: 150-158.
23. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-3284.
24. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
25. Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011; 18: 829-840.
26. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010; 6: 141-152.
27. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011; 146: 53-66.
28. Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ 2014; 21: 1119-1131.
29. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA 2011; 108: 9951-9956.
30. Helczynska K, Kronblad A, Jogi A, Nilsson E, Beckman S, Landberg G et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003; 63: 1441-1444.
31. Jogi A, Ora I, Nilsson H, Poellinger L, Axelson H, Pahlman S. Hypoxia-induced dedifferentiation in neuroblastoma cells. Cancer Lett 2003; 197: 145-150.
32. Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, Cohen-Jonathan-Moyal E. Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1alpha and survivin in U87 cells. Eur J Cancer 2013; 49: 2884-2891.
33. Tabatabai G, Frank B, Mohle R, Weller M, Wick W. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain 2006; 129: 2426-2435.
34. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012; 338: 1080-1084.
35. Kim MJ, Kim RK, Yoon CH, An S, Hwang SG, Suh Y et al. Importance of PKCdelta signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment. J Cell Sci 2011; 124: 3084-3094.
36. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211-9218.
37. Wu Y, Richard JP, Wang SD, Rath P, Laterra J, Xia S. Regulation of glioblastoma multiforme stem-like cells by inhibitor of DNA binding proteins and oligodendroglial lineage-associated transcription factors. Cancer Sci 2012; 103: 1028-1037.
38. Ernst A, Campos B, Meier J, Devens F, Liesenberg F, Wolter M et al. De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene 2010; 29: 3411-3422.
39. Mangiola A, Lama G, Giannitelli C, De Bonis P, Anile C, Lauriola L et al. Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 2007; 13: 6970-6977.
40. Shih AH, Holland EC. Notch signaling enhances nestin expression in gliomas. Neoplasia 2006; 8: 1072-1082.
41. Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ 2014; 21: 258-269.
42. Nielsen JA, Maric D, Lau P, Barker JL, Hudson LD. Identification of a novel oligodendrocyte cell adhesion protein using gene expression profiling. J Neurosci 2006; 26: 9881-9891.
43. Dirks PB. Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philos Trans R Soc Lond B Biol Sci 2008; 363: 139-152.
44. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-129.
45. Zhou X, Zhou YP, Huang GR, Gong BL, Yang B, Zhang DX et al. Expression of the stem cell marker, Nanog, in human endometrial adenocarcinoma. Int JGynecol Pathol 2011; 30: 262-270.
46. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23: 7494-7506.
47. Iscru E, Ahmed T, Coremans V, Bozzi Y, Caleo M, Conway EM et al. Loss of survivin in neural precursor cells results in impaired long-term potentiation in the dentate gyrus and CA1-region. Neuroscience 2013; 231: 413-419.
48. Cui D, Xu Q, Wang K, Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci 2010; 288: 156-166.
49. Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 2013; 19: 631-642.
50. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553-562.
51. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010; 19: 1355-1366.
52. Jeong JC, Kim MS, Kim TH, Kim YK. Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells. Neurochem Res 2009; 34: 991-1001.
53. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
54. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
55. Sherriff J, Tamangani J, Senthil L, Cruickshank G, Spooner D, Jones B et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol 2013; 86: 20120414.
56. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-2728.
57. Zhuang W, Li B, Long L, Chen L, Huang Q, Liang Z. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 2011; 129: 2720-2731.
58. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells 2012; 30: 833-844.
59. Ju JH, Yang W, Oh S, Nam K, Lee KM, Noh DY et al. HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage. Biochem J 2013; 451: 123-134.
60. Wen K, Fu Z, Wu X, Feng J, Chen W, Qian J. Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. Cancer Lett 2013; 333: 56-65.
61. Feng R, Zhou S, Liu Y, Song D, Luan Z, Dai X et al. Sox2 protects neural stem cells from apoptosis via up-regulating survivin expression. Biochem J 2013; 450: 459-468.
62. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012; 14: 120-128.
63. Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH. Treat cancers by targeting survivin: Just a dream or future reality? Cancer Treat Rev 2013; 39: 802-811.
64. Reichert S, Rodel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M et al. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 2011; 101: 51-58.
65. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011; 16: 485-494.
66. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008; 26: 3027-3036.
67. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA 2013; 110: 6829-6834.
68. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C et al. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol 2011; 22: 159-174.
69. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 2011; 108: 16062-16067.
70. Lemarie A, Morzadec C, Bourdonnay E, Fardel O, Vernhet L. Human macrophages constitute targets for immunotoxic inorganic arsenic. J Immunol 2006; 177: 3019-3027.
71. Monferran S, Skuli N, Delmas C, Favre G, Bonnet J, Cohen-Jonathan-Moyal E et al. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer 2008; 123: 357-364.
72. Mlynarik V, Cudalbu C, Clement V, Marino D, Radovanovic I, Gruetter R. In vivo metabolic profiling of glioma-initiating cells using proton magnetic resonance spectroscopy at 14.1 Tesla. NMR Biomed 2012; 25: 506-513.
73. Auvergne RM, Sim FJ, Wang S, Chandler-Militello D, Burch J, Al Fanek Y et al. Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 2013; 3: 2127-2141.
74. Lemarie A, Huc L, Pazarentzos E, Mahul-Mellier AL, Grimm S. Specific disintegration of complex II succinate:ubiquinone oxidoreductase links pH changes to oxidative stress for apoptosis induction. Cell Death Differ 2011; 18: 338-349.